The 2026 Healthtech Messaging Index
Proscia
proscia.com·scored August 23, 2026
25/38
Approaching
Close. The bones are good. A few targeted fixes on the weakest signals would push Proscia into magnetic territory.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Digital pathology platform / computational pathology software for clinical diagnosis and biopharma drug development, it named:
Buyer we put in the prompt: VP/Director of Pathology, Lab Director, or Head of Translational Research at a top-20 pharma company, large hospital system, or clinical reference lab. Both the buyer and the category were inferred from Proscia’s homepage alone. The model had no web access.
Proscia was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI mentioned you for "Digital pathology platform / computational pathology software for clinical diagnosis and biopharma drug development", but only generically: "Proscia offers a digital pathology platform called Concentriq aimed at enterprise-scale image management and AI integration for both research and clinical pathology workflows.". You're on the radar, but AI doesn't yet repeat your specific positioning back.
Overall assessment
Proscia's biggest strength is its trust architecture: named customers with titles, a KLAS #1 ranking, FDA clearance, hard adoption metrics (12M cases, 30K+ studies), and a video series that gives customers a real voice ... together these make the page unusually credible for a regulated-market B2B. The biggest gap is zero cost-of-inaction framing and no competitive acknowledgment: the page never tells a buyer what they lose by waiting or what makes Concentriq the right choice over Philips, Leica, or the status quo of glass slides, which means it converts believers but fails to create urgency for fence-sitters.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
05Problem Leadership
“Hero opens with "Intelligence for the Decisions that Matter Most" ... no problem statement precedes the solution.”
The page leads entirely with the solution and platform brand; the buyer's problem is never articulated in their own language before Proscia's capabilities are presented.
All 19 signals, scored 0 to 2.
Total 25/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Intelligence for the Decisions that Matter Most" / "Pathology's AI platform for the experts answering medicine's biggest questions”
The vertical (pathology) and audience (experts) emerge quickly, but 'decisions that matter most' is abstract poetry, not a caveman-clear problem statement ... a stranger still can't snap-identify what the product does in 7 seconds.
- 1
02Rebellion / Movement
“a pathology platform with AI bolted on can't keep up”
There is a named status quo being rejected ('AI bolted on'), but the enemy is only named once, buried in a webinar blurb, not built into the hero as a central rebellion that frames everything.
- 2
03Owned Language & Category
“Concentriq" / "Pathology AI for Precision Medicine" / "Fifth Generation of Concentriq" / "computational pathology”
Proscia owns 'Concentriq' as a named platform brand, coins 'Fifth Generation of Concentriq,' and stakes a category claim in 'computational pathology' and 'Pathology AI for Precision Medicine' ... language specific enough for an AI to quote back and attribute uniquely.
- 1
04ICP Clarity
“for biopharma" / "16 of 20 top pharmaceutical companies" / "over 4,000 hospitals and clinics globally”
Two distinct audiences (biopharma and clinical labs) are present, but no role-level ICP clarity ... the page never addresses a VP of Pathology, a Lab Director, or a Head of Translational Research by name or pain, leaving buyers to self-select through solution tiles.
- 0
05Problem Leadershipweakest
“Hero opens with "Intelligence for the Decisions that Matter Most" ... no problem statement precedes the solution.”
The page leads entirely with the solution and platform brand; the buyer's problem is never articulated in their own language before Proscia's capabilities are presented.
- 2
06Solution Clarity
“The Concentriq portfolio powers precision medicine from discovery through diagnosis, with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review.”
A visitor can repeat exactly what Concentriq does after one read ... the sentence is specific, complete, and covers both use-case families without jargon overload.
- 0
07Cost of Inaction
“No mention of what happens to labs, trials, or patients if digitization is delayed or if a competing platform is used instead.”
The page never names the cost of inaction ... no missed trial timelines, no diagnostic delays, no failed biomarker studies ... so there is zero urgency driving a buyer to act now.
- 1
08Promised Land
“Turn tissue into biomarker insights, move therapies through development and get them to the patients who need them.”
A promised land exists for the life sciences buyer but is vague for the clinical buyer; neither vision is painted with enough specificity (time saved, outcomes achieved) to feel concrete and aspirational.
Trust Signal
4 signals
- 2
09Proof & Evidence
“12M cases managed annually" / "4,000+ hospitals and clinics" / "30,000+ studies powered" / "100% of customers told KLAS they would buy Concentriq again”
Multiple concrete, named metrics with scale and an independent-source KLAS stat constitute genuine proof ... not adjectives ... and the numbers are specific enough to be credible.
- 2
10Social Proof
“Dr. Luis Cano, Clinical AI & Digital Pathology Consultant" / "Dr. Cherub Kim, Director, Medical Affairs" at Labcorp / "Dr. Amanda Hemmerich, Global Director of Digital Pathology Innovation, IQVIA”
Named doctors with titles and company affiliations, plus a dedicated video series ('Feats of Strength'), and recognizable logos (Bayer, Lilly, BMS, Cleveland Clinic) make social proof strong and specific.
- 2
11Authority & Credibility
“Best in KLAS 2026 ... Concentriq is the highest-rated digital pathology platform in both the United States and Europe”
An independent, third-party analyst award with a named ranking body (KLAS) and a quantified claim (#1) demonstrates authority rather than claiming it, and FDA 510(k) clearance adds regulatory credibility.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or the 'do nothing' option anywhere on the page.”
The page never acknowledges that buyers could choose Philips, Leica, or legacy glass slides ... alternatives are completely ignored, which signals low confidence and leaves competitive objections unaddressed.
AI Signal
6 signals
- 1
13Customer Focus
“Behind every successful digital pathology deployment is a pathologist or lab leader who broke down barriers" (Feats of Strength section)”
The Feats of Strength section genuinely centers the customer as hero, but the majority of the page ... hero, stats block, platform description ... tells Proscia's story about capabilities and scale, so the page tilts toward the company.
- 2
14AI-Parmesan Index
“an enterprise AI layer at its core" / "computational pathology is essential to understand disease, select patients, and ensure trials succeed”
AI is tied to specific, mechanistic outcomes (patient selection, trial success, biomarker insights) rather than sprinkled as a marketing adjective, and the legal footnote clarifying which modules are AI vs. not adds credibility rather than noise.
- 2
15LLM Quotability
“16 of the top 20 pharma companies and over 4,000 hospitals and clinics globally" / "100% of customers told KLAS they would buy Concentriq again”
Several sentences are clean, declarative, and citation-ready ... an LLM recommending digital pathology platforms could lift these verbatim with named source attribution (KLAS).
- 2
16Copyright Freshness
“Best in KLAS 2026" / blog post and press release content visible with recent publication context (FDA clearance, Fifth Generation launch)”
A 2026 award, a current FDA press release, and fresh blog content signal recency; the page shows active publication cadence that AI engines weight positively.
- 2
17Entity Distinctiveness
“Pathology's AI platform" + "Concentriq" + "FDA 510(k) clearance" + "Best in KLAS 2026" + "16 of 20 top pharma" + "Feats of Strength”
The combination of a proprietary named platform, a regulatory clearance, a specific KLAS ranking, a pharma penetration stat, and an original content series creates a fingerprint no competitor could claim ... an AI could only attribute this description to Proscia.
- 1
18AI Recommendation Check
“AI named you alongside Philips Digital Pathology, Leica Biosystems (Aperio/Veritas), Hamamatsu (NDP), Paige AI, PathAI, describing you as: "Proscia offers a digital pathology platform called Concentriq aimed at enterprise-scale image management and AI integration for both research and clinical pathology workflows.".”
AI mentioned you for "Digital pathology platform / computational pathology software for clinical diagnosis and biopharma drug development", but only generically: "Proscia offers a digital pathology platform called Concentriq aimed at enterprise-scale image management and AI integration for both research and clinical pathology workflows.". You're on the radar, but AI doesn't yet repeat your specific positioning back.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“EXPLORE CONCENTRIQ" (primary CTA) / "READ THE KLAS REPORT" / "SEE THEIR STORIES" ... no numbered process or path visible.”
There are multiple CTAs but no single dominant primary paired with one soft secondary, and there is no visible numbered process explaining how a buyer gets started ... so the conversion architecture is scattered rather than guided.
Keep the lead
AI already names Proscia. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Proscia the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.